Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 6/2016

01-12-2016 | Original Paper

DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up

Authors: Elisabetta Bigagli, Carlotta De Filippo, Cinzia Castagnini, Simona Toti, Francesco Acquadro, Francesco Giudici, Marilena Fazi, Piero Dolara, Luca Messerini, Francesco Tonelli, Cristina Luceri

Published in: Cellular Oncology | Issue 6/2016

Login to get access

Abstract

Background

DNA copy number alterations (CNAs) and gene expression changes have amply been encountered in colorectal cancers (CRCs), but the extent at which CNAs affect gene expression, as well as their relevance for tumor development, are still poorly defined. Here we aimed at assessing the clinical relevance of these parameters in a 10 year follow-up study.

Methods

Tumors and normal adjacent colon mucosa, obtained at primary surgery from 21 CRC patients, were subjected to (i) high-resolution array CGH (a-CGH) for the detection of CNAs and (ii) microarray-based transcriptome profiling for the detection of gene expression (GE) changes. Correlations between these genomic and transcriptomic changes and their associations with clinical and histopathological parameters were assessed with the aim to identify molecular signatures associated with disease-free survival of the CRC patients during a 10 year follow-up.

Results

DNA copy number gains were frequently detected in chromosomes 7, 8q, 13, 19, 20q and X, whereas DNA copy number losses were frequently detected in chromosomes 1p, 4, 8p, 15, 17p, 18, 19 and 22q. None of these alterations were observed in all samples. In addition, we found that 2,498 genes were up- and that 1,094 genes were down-regulated in the tumor samples compared to their corresponding normal mucosa (p < 0.01). The expression of 65 genes was found to be significantly associated with prognosis (p < 0.01). Specifically, we found that up-regulation of the IL17RA, IGF2BP2 and ABCC2 genes, and of genes acting in the mTOR and cytokine receptor pathways, were strongly associated with a poor survival. Subsequent integrated analyses revealed that increased expression levels of the MMP9, BMP7, UBE2C, I-CAM, NOTCH3, NOTCH1, PTGES2, HMGB1 and ERBB3 genes were associated with copy number gains, whereas decreased expression levels of the MUC1, E2F2, HRAS and SIRT3 genes were associated with copy number losses. Pathways related to cell cycle progression, eicosanoid metabolism, and TGF-β and apoptosis signaling, were found to be most significantly affected.

Conclusions

Our results suggest that CNAs in CRC tumor tissues are associated with concomitant changes in the expression of cancer-related genes. In other genes epigenetic mechanism may be at work. Up-regulation of the IL17RA, IGF2BP2 and ABCC2 genes, and of genes acting in the mTOR and cytokine receptor pathways, appear to be associated with a poor survival. These alterations may, in addition to Dukes' staging, be employed as new prognostic biomarkers for the prediction of clinical outcome in CRC patients.
Literature
1.
K.W. Kinzler, B. Vogelstein, Lessons from hereditary colorectal cancer. Cell 87(2), 159–170 (1996)CrossRefPubMed
2.
H.R. Oh, C.H. An, N.J. Yoo, S.H. Lee, Somatic mutations of amino acid metabolism-related genes in gastric and colorectal cancers and their regional heterogeneity - a short report. Cell. Oncol. 37(6), 455–61 (2014)
3.
4.
T. Ried, R. Knutzen, R. Steinbeck, H. Blegen, E. Schröck, K. Heselmeyer, S. du Manoir, G. Auer, Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 15(4), 234–245 (1996)CrossRefPubMed
5.
C. Lengauer, K.W. Kinzler, B. Vogelstein, Genetic instability in colorectal cancers. Nature 386, 623–627 (1997)CrossRefPubMed
6.
A. Goel, C.N. Arnold, D. Niedzwiecki, D.K. Chang, L. Ricciardiello, J.M. Carethers, J.M. Dowell, L. Wasserman, C. Compton, R.J. Mayer, M.M. Bertagnolli, C.R. Boland, Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 63(7), 1608–1614 (2003)PubMed
7.
Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330–337 (2012)CrossRef
8.
M. Nakao, S. Kawauchi, T. Furuya, T. Uchiyama, J. Adachi, T. Okada, K. Ikemoto, A. Oga, K. Sasaki, Identification of DNA copy number aberrations associated with metastases of colorectal cancer using array CGH profiles. Cancer Genet. Cytogenet. 188(2), 70–76 (2009)CrossRefPubMed
9.
S. Lassmann, R. Weis, F. Makowiec, J. Roth, M. Danciu, U. Hopt, M. Werner, C.G.H. Array, Identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J. Mol. Med. (Berl) 85(3), 293–304 (2007)CrossRef
10.
A.M. Jones, E.J. Douglas, S.E. Halford, H. Fiegler, P.A. Gorman, R.R. Roylance, N.P. Carter, I.P. Tomlinson, Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene 24(1), 118–129 (2005)CrossRefPubMed
11.
Q.J. He, W.F. Zeng, J.S. Sham, D. Xie, X.W. Yang, H.L. Lin, W.H. Zhan, F. Lin, S.D. Zeng, D. Nie, L.F. Ma, C.J. Li, S. Lu, X.Y. Guan, Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet. Cytogenet. 144(2), 112–118 (2003)CrossRefPubMed
12.
L. Marisa, A. de Reyniès, A. Duval, J. Selves, M.P. Gaub, L. Vescovo, M.C. Etienne-Grimaldi, R. Schiappa, D. Guenot, M. Ayadi, S. Kirzin, M. Chazal, J.F. Fléjou, D. Benchimol, A. Berger, A. Lagarde, E. Pencreach, F. Piard, D. Elias, Y. Parc, S. Olschwang, G. Milano, P. Laurent-Puig, V. Boige, Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10(5), e1001453 (2013)CrossRefPubMedPubMedCentral
13.
K.H. Koh, H. Rhee, H.J. Kang, E. Yang, K.T. You, H. Lee, B.S. Min, N.K. Kim, S.W. Nam, H. Kim, Differential gene expression profiles of metastases in paired primary and metastatic colorectal carcinomas. Oncology 75(1–2), 92–101 (2008)CrossRefPubMed
14.
D. Cavalieri, P. Dolara, E. Mini, C. Luceri, C. Castagnini, S. Toti, K. Maciag, C. De Filippo, S. Nobili, M. Morganti, C. Napoli, G. Tonini, M. Baccini, A. Biggeri, F. Tonelli, R. Valanzano, C. Orlando, S. Gelmini, F. Cianchi, L. Messerini, L. Luzzatto, Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer. Oncol. Res. 16(11), 535–548 (2007)CrossRefPubMed
15.
M. Grade, P. Hörmann, S. Becker, A.B. Hummon, D. Wangsa, S. Varma, R. Simon, T. Liersch, H. Becker, M.J. Difilippantonio, B.M. Ghadimi, T. Ried, Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res. 67(1), 41–56 (2007)CrossRefPubMedPubMedCentral
16.
M.L. Slattery, J.S. Herrick, L.E. Mullany, J.R.K. Gertz, Wolff Improved survival among colon cancer patients with increased differentially expressed pathways. BMC Med 13, 75 (2015)CrossRefPubMedPubMedCentral
17.
T.H. Agesen, A. Sveen, M.A. Merok, G.E. Lind, A. Nesbakken, R.I. Skotheim, R.A. Lothe, ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 61(11), 1560–1567 (2012)CrossRefPubMed
18.
P. Platzer, M.B. Upender, K. Wilson, J. Willis, J. Lutterbaugh, A. Nosrati, J.K. Willson, D. Mack, T. Ried, S. Markowitz, Silence of chromosomal amplifications in colon cancer. Cancer Res. 62(4), 1134–1138 (2002)PubMed
19.
H. Brim, M.S. Abu-Asab, M. Nouraie, J. Salazar, J. Deleo, H. Razjouyan, P. Mokarram, A.A. Schaffer, F. Naghibhossaini, H. Ashktorab, An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors. PLoS One 9(1), e82185 (2014)CrossRefPubMedPubMedCentral
20.
K.K. Lagerstedt, E. Kristiansson, C. Lönnroth, M. Andersson, B.M. Iresjö, A. Gustafsson, E. Hansson, U. Kressner, S. Nordgren, F. Enlund, K. Lundholm, Genes with relevance for early to late progression of colon carcinoma based on combined genomic and transcriptomic information from the same patients. Cancer Inform. 9, 79–91 (2010)PubMedPubMedCentral
21.
M. Sheffer, M.D. Bacolod, O. Zuk, S.F. Giardina, H. Pincas, F. Barany, P.B. Paty, W.L. Gerald, D.A. Notterman, E. Domany, Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 106(17), 7131–7136 (2009)CrossRefPubMedPubMedCentral
22.
D. Tsafrir, M. Bacolod, Z. Selvanayagam, I. Tsafrir, J. Shia, Z. Zeng, H. Liu, C. Krier, R.F. Stengel, F. Barany, W.L. Gerald, P.B. Paty, E. Domany, D.A. Notterman, Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res. 66(4), 2129–2137 (2006)CrossRefPubMed
23.
J. Camps, Q.T. Nguyen, H.M. Padilla-Nash, T. Knutsen, N.E. McNeil, D. Wangsa, A.B. Hummon, M. Grade, T. Ried, M.J. Difilippantonio, Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer 48(11), 1002–1017 (2009)CrossRefPubMedPubMedCentral
24.
L.W. Loo, M. Tiirikainen, I. Cheng, A. Lum-Jones, A. Seifried, J.M. Church, R. Gryfe, D.J. Weisenberger, N.M. Lindor, S. Gallinger, R.W. Haile, D.J. Duggan, S.N. Thibodeau, G. Casey, L. Le Marchand, Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable CpG island methylator phenotype-negative colon cancer. Genes Chromosomes Cancer 52(5), 450–466 (2013)CrossRefPubMedPubMedCentral
25.
P.H. Eilers, R.X. de Menezes, Quantile smoothing of array CGH data. Bioinformatics 21(7), 1146–53 (2005)CrossRefPubMed
26.
C. Rouveirol, N. Stransky, P. Hupé, P.L. Rosa, E. Viara, E. Barillot, F. Radvanyi, Computation of recurrent minimal genomic alterations from array-CGH data. Bioinformatics 22(7), 849–856 (2006)CrossRefPubMed
27.
N.Z. Ali Hassan, N.M. Mokhtar, T. Kok Sin, I. Mohamed Rose, I. Sagap, R. Harun, R. Jamal, Integrated analysis of copy number variation and genome-wide expression profiling in colorectal cancer tissues. PLoS One 9(4), e92553 (2014)CrossRefPubMedPubMedCentral
28.
T. Sen, N. Sen, M.G. Noordhuis, R. Ravi, T.C. Wu, P.K. Ha, D. Sidransky, M.O. Hoque, OGDHL is a modifier of AKT-dependent signaling and NF-kB function. PLoS One 7(11), e48770 (2012)CrossRefPubMedPubMedCentral
29.
Y. Tang, A. Puri, M.D. Ricketts, T.S. Rai, J. Hoffmann, E. Hoi, P.D. Adams, D.C.R. Schultz, Marmorstein Identification of an ubinuclein 1 region required for stability and function of the human HIRA/UBN1/CABIN1/ASF1a histone H3.3 chaperone complex. Biochemistry 51(12), 2366–2377 (2012)CrossRefPubMedPubMedCentral
30.
Y. Iwakura, H. Ishigame, S. Saijo, S. Nakae, Functional specialization of interleukin-17 family members. Immunity 34(2), 149–162 (2011)CrossRefPubMed
31.
K. Vazquez-Santillan, J. Melendez-Zajgla, L. Jimenez-Hernandez, G. Martínez-Ruiz, V. Maldonado, NF-kB signaling in cancer stem cells: a promising therapeutic target? Cell. Oncol. 38(5), 327–39 (2015)
32.
K. Wang, M. Karin, The IL-23 to IL-17 cascade inflammation-related cancers. Clin. Exp. Rheumatol. 33(4 Suppl 92), S87–90 (2015)PubMed
33.
Z. Tong, X.O. Yang, H. Yan, W. Liu, X. Niu, Y. Shi, W. Fang, B. Xiong, Y. Wan, C. Dong, A protective role by interleukin-17 F in colon tumorigenesis. PLoS One 7(4), e34959 (2012)CrossRefPubMedPubMedCentral
34.
R. Liao, J. Sun, H. Wu, Y. Yi, J.X. Wang, H.W. He, X.Y. Cai, J. Zhou, Y.F. Cheng, J. Fan, S.J. Qiu, High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 11, 32–33 (2013)
35.
M.C. Honorati, L. Cattini, A. Facchini, Possible prognostic role of IL-17R in osteosarcoma. J. Cancer Res. Clin. Oncol. 133(12), 1017–1021 (2007)CrossRefPubMed
36.
Y.X. Jiang, P.A. Li, S.W. Yang, Y.X. Hao, P.W. Yu, Increased chemokine receptor IL-17RA expression is associated with poor survival in gastric cancer patients. Int. J. Clin. Exp. Pathol. 8(6), 7002–7008 (2015)PubMedPubMedCentral
37.
K. Wang, M.K. Kim, G. Di Caro, J. Wong, S. Shalapour, J. Wan, W. Zhang, Z. Zhong, E. Sanchez-Lopez, L.W. Wu, K. Taniguchi, Y. Feng, E. Fearon, S.I. Grivennikov, M. Karin, Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41(6), 1052–1063 (2014)CrossRefPubMedPubMedCentral
38.
Y. Xie, W. Sheng, J. Xiang, Z. Ye, J. Yang, Interleukin-17 F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest. 28(6), 598–607 (2010)CrossRefPubMed
39.
40.
E. Hinoshita, T. Uchiumi, K. Taguchi, N. Kinukawa, M. Tsuneyoshi, Y. Maehara, K.M. Sugimachi, Kuwano increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res. 6, 2401–2407 (2000)PubMed
41.
I. Hlavata, B. Mohelnikova-Duchonova, R. Vaclavikova, V. Liska, P. Pitule, P. Novak, J. Bruha, O. Vycital, L. Holubec, V. Treska, P. Vodicka, P. Soucek, The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 27(2), 187–196 (2012)CrossRefPubMed
42.
A. Barghash, V. Helms, S.M. Kessler, Overexpression of IGF2 mRNA-binding protein 2 (IMP2/p62) as a feature of basal-like breast cancer correlates with short survival. Scand. J. Immunol. 82(2), 142–143 (2015)CrossRefPubMed
43.
B. Davidson, Y.B. Rosenfeld, A. Holth, E. Hellesylt, C.G. Tropé, R. Reich, J.K. Yisraeli, VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. Hum. Pathol. 45(7), 1520–1528 (2014)CrossRefPubMed
44.
S.M. Kessler, J. Pokorny, V. Zimmer, S. Laggai, F. Lammert, R.M. Bohle, A.K. Kiemer, IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 304(4), G328–336 (2013)CrossRefPubMed
45.
B.M. Wolpin, K. Ng, A.X. Zhu, T. Abrams, P.C. Enzinger, N.J. McCleary, D. Schrag, E.L. Kwak, J.N. Allen, P. Bhargava, J.A. Chan, W. Goessling, L.S. Blaszkowsky, J.G. Supko, M. Elliot, K. Sato, E. Regan, J.A. Meyerhardt, C.S. Fuchs, Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 18(4), 377–378 (2013)CrossRefPubMedPubMedCentral
46.
Z. Niu, J. Wang, S. Muhammad, W. Niu, E. Liu, C. Peng, B. Liang, Q. Sun, S. Obo, Z. He, S. Liu, X. Zou, J. Niu, Protein expression of eIF4E and integrin αvβ6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction. Cell Biosci. 4, 23 (2014)CrossRefPubMedPubMedCentral
47.
A. Nastase, L. Paslaru, V. Herlea, M. Ionescu, D. Tomescu, N. Bacalbasa, S. Dima, I. Popescu, Expression of interleukine-8 as an independent prognostic factor for sporadic colon cancer dissemination. J. Med. Life 7(2), 215–219 (2014)PubMedPubMedCentral
48.
F. Puca, M. Colamaio, A. Federico, M. Gemei, N. Tosti, A.U. Bastos, L. Del Vecchio, S. Pece, S. Battista, A. Fusco, HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. Oncotarget 5(10), 3234–3245 (2014)CrossRefPubMedPubMedCentral
49.
A.Z. Gimeno-García, A. Santana-Rodríguez, A. Jiménez, A. Parra-Blanco, D. Nicolás-Pérez, C. Paz-Cabrera, F. Díaz-González, C. Medina, L. Díaz-Flores, E. Quintero, Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. Eur. J. Cancer 42(18), 3246–3252 (2006)CrossRefPubMed
50.
W.J. Lubbe, Z.Y. Zhou, W. Fu, D. Zuzga, S. Schulz, R. Fridman, R.J. Muschel, S.A. Waldman, G.M. Pitari, Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin. Cancer Res. 12(6), 1876–82 (2006)CrossRefPubMed
51.
Y. Takahashi, Y. Ishii, Y. Nishida, M. Ikarashi, T. Nagata, T. Nakamura, S. Yamamori, S. Asai, Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH. Cancer Genet. Cytogenet. 168(1), 30–35 (2006)CrossRefPubMed
52.
M. Aoki, S. Ishigami, Y. Uenosono, T. Arigami, Y. Uchikado, Y. Kita, H. Kurahara, M. Matsumoto, S. Ueno, S. Natsugoe, Expression of BMP-7 in human gastric cancer and its clinical significance. Br. J. Cancer 104(4), 714–718 (2011)CrossRefPubMedPubMedCentral
53.
V. Serafin, L. Persano, L. Moserle, G. Esposito, M. Ghisi, M. Curtarello, L. Bonanno, M. Masiero, D. Ribatti, M. Stürzl, E. Naschberger, R.S. Croner, A.M. Jubb, A.L. Harris, H.S. Koeppen, A. Amadori, Indraccolo Notch3 signalling promotes tumour growth in colorectal cancer. J. Pathol. 224, 448–460 (2011)CrossRefPubMed
54.
K. Howard, K.K. Lo, L. Ao, F. Gamboni, B.H. Edil, R. Schulick, C.C. Barnett Jr., Intercellular adhesion molecule-1 mediates murine colon adenocarcinoma invasion. J. Surg. Res. 187(1), 19–23 (2014)CrossRefPubMed
55.
F. Lédel, M. Hallström, P. Ragnhammar, K. Öhrling, D. Edler, HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. Eur. J. Cancer 50(3), 656–662 (2014)CrossRefPubMed
56.
M. Murakami, K. Nakashima, D. Kamei, S. Masuda, Y. Ishikawa, T. Ishii, Y. Ohmiya, K. Watanabe, I. Kudo, Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and −2. J. Biol. Chem. 278(39), 37937–37947 (2003)CrossRefPubMed
57.
K. Yoshimatsu, D. Golijanin, P.B. Paty, R.A. Soslow, P.J. Jakobsson, R.A. DeLellis, K. Subbaramaiah, A.J. Dannenberg, Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 7(12), 3971–3976 (2001)PubMed
58.
G. Ramamoorthi, N. Sivalingam, Molecular mechanism of TGF-β signaling pathway in colon carcinogenesis and status of curcumin as chemopreventive strategy. Tumour Biol. 35(8), 7295–7305 (2014)CrossRefPubMed
59.
60.
A. Kikuchi, T. Ishikawa, K. Mogushi, M. Ishiguro, S. Iida, H. Mizushima, H. Uetake, H. Tanaka, K. Sugihara, Identification of NUCKS1 as a colorectal cancer prognostic marker through integrated expression and copy number analysis. Int. J. Cancer 132(10), 2295–2302 (2013)CrossRefPubMed
61.
C. Xu, Y. Liu, P. Wang, W. Fan, T.C. Rue, M.P. Upton, J.R. Houck, P. Lohavanichbutr, D.R. Doody, N.D. Futran, L.P. Zhao, S.M. Schwartz, C. Chen, E. Méndez, Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival. Mol. Cancer 9, 143 (2010)CrossRefPubMedPubMedCentral
62.
H.M. Horlings, C. Lai, D.S. Nuyten, H. Halfwerk, P. Kristel, E. van Beers, S.A. Joosse, C. Klijn, P.M. Nederlof, M.J. Reinders, L.F. Wessels, M.J. van de Vijver, Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients. Clin. Cancer Res. 16(2), 651–663 (2010)CrossRefPubMed
63.
E. Yiannakopoulou, Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents--implications for cancer treatment and chemoprevention. Cell. Oncol. 37(3), 167–78 (2014)
64.
N. Nishida, S. Yamashita, K. Mimori, T. Sudo, F. Tanaka, K. Shibata, H. Yamamoto, H. Ishii, Y. Doki, M. Mori, MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann. Surg. Oncol. 19(9), 3065–3071 (2012)CrossRefPubMed
65.
T. Zhou, G. Zhang, Z. Liu, S. Xia, H. Tian, Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int. J. Colorectal Dis. 28, 19–24 (2013)CrossRefPubMed
66.
T. Zhou, G.J. Zhang, H. Zhou, H.X. Xiao, Y. Li, Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur. J. Gastroenterol. Hepatol. 26(2), 229–33 (2014)CrossRefPubMed
Metadata
Title
DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up
Authors
Elisabetta Bigagli
Carlotta De Filippo
Cinzia Castagnini
Simona Toti
Francesco Acquadro
Francesco Giudici
Marilena Fazi
Piero Dolara
Luca Messerini
Francesco Tonelli
Cristina Luceri
Publication date
01-12-2016
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 6/2016
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0299-z

Other articles of this Issue 6/2016

Cellular Oncology 6/2016 Go to the issue

Review

The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery

Original Paper

NFκB activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy

Original Paper

Identification of genetic variation in the lncRNA HOTAIR associated with HPV16-related cervical cancer pathogenesis

Original Paper

The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells

report

Estrogen receptor expression and gene promoter methylation in non-small cell lung cancer - a short report

Original Paper

Are disseminated tumor cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits